AgomAb Therapeutics (NASDAQ:AGMB) Sets New 12-Month High – Here’s What Happened

AgomAb Therapeutics NV (NASDAQ:AGMB)’s stock price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $17.82 and last traded at $17.82, with a volume of 198739 shares traded. The stock had previously closed at $13.81.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on AGMB shares. Zacks Research raised AgomAb Therapeutics to a “hold” rating in a research note on Wednesday, March 4th. HC Wainwright started coverage on AgomAb Therapeutics in a report on Monday, June 22nd. They set a “buy” rating and a $35.00 price objective on the stock. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, AgomAb Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $32.75.

AgomAb Therapeutics Stock Down 8.6%

The stock has a 50-day moving average of $11.38.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.